Document is current

Article History

Received: 23 August 2025

Accepted: 5 January 2026

First Online: 5 February 2026

Declarations

:

: Not applicable.

: Not applicable.

: EM has participated in speaker engagements for Eisai, Neurology Live, and Projects in Knowledge-Kaplan. Advisory board roles, consulting, and Data Safety Monitoring Board (DSMB) participation have included relationships with Eli Lilly, Alnylam, Alector, Alzamend, Sanofi, AstraZeneca, Hoffmann-La Roche, Grifols, Johnson and Johnson, Vigil Neuroscience and Merck. There are several inventions that have been filed by Washington University for patents, including “Methods of diagnosing AD with phosphorylation changes” and “Methods to detect MTBR-tau isoforms and use”. These intellectual properties owned by Washington University can be or are licensed and some licensing income may be distributed to EM and other inventors. These intellectual properties being licensed by Washington University from C2N and currently being utilized in research have been reviewed by the Washington University COI and ICOI committees. All co-inventors, including some lab members, the University, and EM could receive part of the profits from any sales of these tests by C2N, which is in the process of licensing or has licensed some IP from the University. These activities have been reviewed by Washington University’s (WU) Conflicts of Interest Review Committee in accordance with WU’s Research Conflicts of Interest Policy and WU’s Institutional Conflict of Interest Review Committee in accordance with WU’s Institutional Conflict of Interest Policy. CJM has provided consultancy to Alector, Biogen, Eisai, Ionis, Lilly, MSD, Neurimmune, Novartis, Prevail, Roche/Genentech, Wave. She is an advisor to the Drug Delivery Foundation. She has received honoraria for teaching and education from Biogen, Eisai and Lilly, and received academic funding award from Biogen. MS has served/serves on advisory boards for Arvakor, Eli Lilly and Company, Novo Nordisk and Roche, received honoraria for presentations or educational material from Bioarctic, Novo Nordisk, Eli Lilly and Company, Roche and Triolabs, and receives research support (to the institution) from Beckman Coulter, Bioarctic, Novo Nordisk and Roche. He is co-founder and shareholder of Centile Bioscience and serves as Associate Editor with Alzheimer’s Research & Therapy. KRW is a full-time employee of Eisai, Inc. RWP has received honoraria from GE Healthcare for academic talks and co-leads the Neurofilament light consortium which receives funding from Abbvie, Biogen, Bristol Myers Squibb and Roche. RWP holds shares in and has consulted for Guilford street laboratories limited.